Annexon, Inc. - common stock (ANNX)

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome. Love described A

In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive technical breakout followed the announcement that Biogen (Nasdaq: BIIB) has entered into a definitive agreement to acquire the leader

ANNX stock results show that Annexon met analyst estimates for earnings per share the second quarter of 2024.

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.

Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 trial endpoints.

While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification.

Annexon reports positive Phase 3 trial results for ANX005 in Guillain-Barré syndrome, showing significant improvements in disability, muscle strength, and ventilation duration.